Skip to main content
SpringerLink
Log in

Drug Therapy for Geriatric Depression

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Depression is a common problem in elderly patients. The identification and treatment of depression may be more complex in older than in younger patients because of co-existing illnesses and concurrent drug therapy. In addition, a variety of medical conditions and drugs can cause depression.

The pharmacology and pharmacokinetics of the cyclic antidepressants have been extensively studied. These agents are hepatically metabolised, often to an active agent. The clearance of the parent compound and the active metabolite(s) may be reduced in elderly patients, causing drug accumulation and increased toxicity. The cyclic antidepressants interact with a variety of neurotransmitters and their receptors. While these effects explain many of the adverse effects of the cyclic antidepressants, it is not clear whether the noradrenergic and serotoninergic effects of such drugs explain their antidepressant effects.

Cyclic antidepressant therapy is associated with a variety of adverse effects, including sedation, anticholinergic effects and effects caused by α-adrenergic blockade. The cyclic antidepressants differ in their relative ability to cause these adverse effects. The newer cyclic antidepressants such as the selective serotonin reuptake inhibitors are relatively free of sedative and anticholinergic effects, but cause insomnia, nausea and possibly cardiac arrhythmias. All cyclic antidepressants appear to be equally effective. Therefore, the choice of a cyclic antidepressant for a specific patient must be based on several factors, including the risk of adverse effects.

In elderly patients, the initial dose of cyclic antidepressants should be lower than the usual dose recommended for younger adults, and titrated slowly. All antidepressants require at least 2 to 3 weeks for their antidepressant effects to be seen. Because depression is a relapsing disease, maintenance antidepressant therapy may be indicated to reduce the risk of recurrent depression.

The monoamine oxidase (MAO) inhibitors are effective antidepressants, especially in atypical depression. However, the adverse effects and risk of potentially lethal drug interactions of the older agents preclude their routine use. However, the new reversible MAO inhibitors may prove to be a well tolerated alternative in older patients.

Antidepressant therapy should not be avoided simply because of a patient’s age. However, the clinician must be conservative in the use of cyclic antidepressants in elderly patients and monitor closely for adverse drug reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alexopoulos GS, Meyers BS, Young RC. Brain changes in geriatric depression. International Journal of Geriatric Psychiatry 3: 157–161, 1988

    Article  Google Scholar 

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., Washington, DC, 1987

  • Amsterdam J, Brunswick D, Mendels J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. American Journal of Psychiatry 137: 653–662, 1980

    PubMed  CAS  Google Scholar 

  • Antidepressant Update. Food and Drug Administration, US Dept of Health and Human Services Publication, T91-64, Rockville, Maryland, 1991

  • Aronson MD, Hafez H. A case of trazodone induced ventricular tachycardia. Journal of Clinical Psychiatry 47: 388–389, 1986

    PubMed  CAS  Google Scholar 

  • Asakura M, Tsukamoto T, Hasegawa K. Modulation of rat brain alpha-2 and beta-adrenergic reception sensitivity following long-term treatment with antidepressants. Brain Research 235: 192–197, 1982

    Article  PubMed  CAS  Google Scholar 

  • Asberg M, Cronholm B, Sjoquist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. British Medical Journal 3: 331–334, 1971

    Article  PubMed  CAS  Google Scholar 

  • Ashford W, Ford CV. Use of MAO inhibitors in elderly patients. American Journal of Psychiatry 136: 1466–1467, 1979

    PubMed  CAS  Google Scholar 

  • Baldessarini RJ. Treatment of depression by altering monoamine metabolism: precursors and metabolic inhibitors. Psychopharmacology Bulletin 20: 224–239, 1984

    PubMed  CAS  Google Scholar 

  • Baldessarini RG. Antidepressant agents. In Chemotherapy in Psychiatry, pp. 130–234, Harvard University Press, Cambridge, Massachusetts, 1985

    Google Scholar 

  • Baldessarini RJ, Marsh E. Fluoxetine and side effects. Archives of General Psychiatry 47: 191–192, 1990

    Article  PubMed  CAS  Google Scholar 

  • Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Ramsey AH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal 303: 685–692, 1991

    Article  PubMed  Google Scholar 

  • Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 481–508, 1986

    Article  PubMed  CAS  Google Scholar 

  • Berezin MA, Liptzin B, Salzman C. The elderly person. In Nicoli Jr (Ed.) The new Harvard guide to psychiatry, pp. 129–138, Harvard University Press, Cambridge, 1988

    Google Scholar 

  • Bernstein JG. Tricyclic and heterocyclic antidepressants. Handbook of drug therapy in Psychiatry, 2nd ed., pp. 123–160, PSG, Littleton, Massachusetts, 1988

    Google Scholar 

  • Biel J. Monoamine oxidase inhibitors antidepressants. In Clark & Del Giudice (Eds) Principles of psychopharmacology, pp. 279–287, Academic Press Inc., New York, 1970

    Google Scholar 

  • Biggs JT, Spiker DG, Petit JM, Ziegler VE. Tricyclic depressant overdose: incidence of symptoms. Journal of the American Medical Association 238: 135–138, 1977

    Article  PubMed  CAS  Google Scholar 

  • Blazer D. Depression in the elderly. New England Journal of Medicine 320: 164–166, 1989

    Article  PubMed  CAS  Google Scholar 

  • Blier P, Chaput Y, de Montigney C. Long-term 5HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of the terminal 5HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedebergs Archives of Pharmacology 337: 246–254, 1988

    CAS  Google Scholar 

  • Borys DJ, Setzer SC, Ling LL. The effects of fluoxetine in the overdose patient. Clinical Toxicology 28: 331–340, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 146: 1352–1353, 1986

    Google Scholar 

  • Bressler R. Antidepressant agents. In Conrad & Bressler (Eds) Drug therapy for the elderly, pp. 295–315, Mosby, St Louis, 1982

    Google Scholar 

  • Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. Journal of Clinical Psychiatry 52: 174–176, 1991

    PubMed  CAS  Google Scholar 

  • Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clinical Pharmacokinetics 18: 434–459, 1990

    Article  PubMed  CAS  Google Scholar 

  • Callaham M. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Annals of Emergency Medicine 14: 1–9, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ciravlo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. Journal of Clinical Psychopharmacology 10: 48–50, 1990

    Article  Google Scholar 

  • Coccaro EF, Siever LJ. Second generation antidepressants: a comparative review. Journal of Clinical Pharmacology 25: 241–260, 1985

    PubMed  CAS  Google Scholar 

  • Cohen D, Eisdorfer C. Major psychiatric and behavioral disorders in the aged. In Andres et al. (Eds) Principles of geriatric medicine, pp. 867–889, McGraw-Hill, New York, 1985

    Google Scholar 

  • Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, et al. Double-blind multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Journal of Clinical Psychiatry 51 (Suppl. 12B): 28–33, 1990

    PubMed  Google Scholar 

  • Cook BL, Helms PM, Smith RE, Tsai M. Unipolar depression in the elderly. Reoccurence on discontinuation of tricyclic antidepressants. Journal of Affective Disorders 10: 91–94, 1986

    Article  PubMed  CAS  Google Scholar 

  • Coppen A, Ghose K, Montgomery S, Rama-Rao VA, Bailey J, et al. Continuation therapy with amitriptyline in depression. British Journal of Psychiatry 133: 28–33, 1978

    Article  PubMed  CAS  Google Scholar 

  • Coyle JT. An introduction to the world of neurotransmitters and neuroreceptors. In Hales & Francis (Eds) APA annual reviews, Vol. 4, pp, 5–94, American Psychiatric Press, Washington, DC, 1985

    Google Scholar 

  • Crooks J, O’Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clinical Pharmacokinetics 1: 280–296, 1976

    Article  PubMed  CAS  Google Scholar 

  • Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. Journal of Clinical Psychopharmacology 8: 347–349, 1988

    Article  PubMed  CAS  Google Scholar 

  • Davidson J. Seizures and bupropion: a review. Journal of Clinical Psychiatry 50: 256–261, 1989

    PubMed  CAS  Google Scholar 

  • de Montigney C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin uptake blockers. Journal of Clinical Psychiatry 51 (Suppl. 12B): 4–8, 1990

    Google Scholar 

  • Debus JR, Rush AJ, Himmel C, Tyler D, Polatin P, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. Journal of Clinical Psychiatry 49: 422–426, 1988

    PubMed  CAS  Google Scholar 

  • Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 225–253, 1991

    Article  PubMed  CAS  Google Scholar 

  • DePrada M, Kettler R, Borkard WP, Lorez HP, Haefly W. Some basic aspects of reversible inhibition of monoamine oxidase-A. Acta Psychiatrica Scandinavica 360 (Suppl.): 7–12, 1990

    Article  Google Scholar 

  • Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression: a perspective on seizures. Archives of General Psychiatry 43: 86–90, 1986

    Article  PubMed  CAS  Google Scholar 

  • DeVanna M, Kummer J, Agnoli A, Gentili P, Lorizio A, et al. Moclobemide compared with second generation antidepressants in elderly people. Acta Psychiatrica Scandinavica 360 (Suppl.): 64–66, 1990

    Article  CAS  Google Scholar 

  • Doogan DP, Caillard V. Sertraline: a new antidepressant. Journal of Clinical Psychiatry 49 (Suppl. 8): 46–51, 1988

    PubMed  Google Scholar 

  • Ereshefsky I, Tran-Johnson T, Davis CM, LeRoy A. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine: new data and review. Clinical Chemistry 34: 863–880, 1988

    PubMed  CAS  Google Scholar 

  • Fabre LF, Putnam HP III. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 48: 406–408, 1987

    PubMed  CAS  Google Scholar 

  • Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? Journal of Clinical Psychiatry 52: 108–111, 1991

    PubMed  CAS  Google Scholar 

  • Feighner JP, Boyer WF, Tyler DL, Heborsky RJ. Fluoxetine and MAOI’s: adverse interactions. Journal of Clinical Psychiatry 51: 222–225, 1990

    PubMed  CAS  Google Scholar 

  • Feighner JP, Cohn JB. Double blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. Journal of Clinical Psychiatry 46: 20–25, 1985

    PubMed  CAS  Google Scholar 

  • Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose: review. Journal of the American Medical Association 257: 521–526, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gabelic I, Kuhn B. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression. Acta Psychiatrica Scandinavica 360 (Suppl.): 63–66, 1990

    Article  PubMed  CAS  Google Scholar 

  • Gardner EA. Effects of bupropion on weight in patients intolerant to previous antidepressants. Current Therapeutic Research 35: 188–199, 1984

    Google Scholar 

  • Gerber PD, Barrett J, Manheimer E, Whiting R, Smith R. Recognition of depression by internists in primary care: a comparison of internists and ‘gold standard’ psychiatric assessments. Journal of General Internal Medicine 4: 7–13, 1989

    Article  PubMed  CAS  Google Scholar 

  • Glassman BH, Bigger T. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Archives of General Psychiatry 38: 815–820, 1981

    Article  PubMed  CAS  Google Scholar 

  • Golden RN, Gilmore JH, Corrigan MHN, Ekstrom RD, Knight BT, et al. Serotonin, suicide and aggression: clinical studies. Journal of Clinical Psychiatry 52 (Suppl. 12): 61–69, 1991

    PubMed  Google Scholar 

  • Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, et al. Psychosis associated with bupropion treatment. American Journal of Psychiatry 142: 1459–1462, 1985

    PubMed  CAS  Google Scholar 

  • Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ, et al. Bupropion in depression. I. Biochemical effects and clinical response. Archives of General Psychiatry 45: 139–143, 1988

    Article  PubMed  CAS  Google Scholar 

  • Guenter TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, et al. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150mg three time a day for 15 days. Acta Psychiatrica Scandinavica 360 (Suppl.): 91–93, 1990

    Article  Google Scholar 

  • Gurland BJ, Meyers BS. Geriatric psychiatry. In Talbott et al. (Eds) Textbook of psychiatry, pp. 1128–1133, American Psychiatric Press, Washington, DC, 1988

    Google Scholar 

  • Gurland BJ, Myers BS. Antidepressant drugs. In Talbott et al. (Eds) Textbook of psychiatry, pp. 788–805, American Psychiatric Press, Washington, DC, 1988

    Google Scholar 

  • Halmi KA, Ackerman S, Gibbs J, Smith G. Basic biologic overview of the eating disorders. In Meltzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1297–1304, Raven Press, New York, 1987

    Google Scholar 

  • Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. In Meltzer (Ed.) Psychopharmacology: the third generation of progress, pp. 535–552, Raven Press, New York, 1987

    Google Scholar 

  • Hollister L, Gsernansky JG. Clinical Pharmacology of Psychotherapeutic Drugs, 3rd ed., pp. 59–96, Churchill Livingstone, New York, 1990

    Google Scholar 

  • Jackson JE. Cardiovascular effects of tricyclic antidepressants. In Ewy & Bressler (Eds) Cardiovascular drugs and the management of heart disease, pp. 285–310, Raven Press, New York, 1982

    Google Scholar 

  • Jefferson JW. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosomatic Medicine 37: 160–179, 1975

    PubMed  CAS  Google Scholar 

  • Jenike MA. Psychoactive drugs in the elderly: antidepressants. Geriatrics 43: 43–53, 1988

    PubMed  CAS  Google Scholar 

  • Johnson JA, Lineberry CG, Ascher JA, Davison J, Khayrallah MA, et al. A 102-center prospective study of seizure in association with bupropion. Journal of Clinical Psychiatry 52: 450–457, 1991

    Google Scholar 

  • Jones JS, Stanley B, Mann JJ, Frances AJ, Guido JR, et al. CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide. American Journal of Psychiatry 147: 1225–1227, 1990

    PubMed  CAS  Google Scholar 

  • Kantor SJ, Glassman AH, Bigger JT, Perel JM, Giardina EV. The cardiac effects of therapeutic plasma concentrations of imipramine. American Journal of Psychiatry 135: 534–538, 1978

    PubMed  CAS  Google Scholar 

  • Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 43 (Suppl. 2): 11–23, 1992

    Article  PubMed  Google Scholar 

  • Katon W, Sullivan MD. Depression and chronic medical illness. Journal of Clinical Psychiatry 51 (Suppl. 3): 11, 1990

    Google Scholar 

  • Keller MB. Depression. Underrecognition and undertreatment by psychiatrists and other health care professionals. Archives of Internal Medicine 150: 946–948, 1990

    Article  PubMed  CAS  Google Scholar 

  • Klerman GL. Depression and related disorders of mood. In Nicoli Jr (Ed.) The new Harvard guide to psychiatry, pp. 309–336, Harvard University Press, Cambridge, Massachusetts, 1988

    Google Scholar 

  • Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES. Treatment of depression by drugs and psychotherapy. American Journal of Psychiatry 131: 186–191, 1974

    PubMed  CAS  Google Scholar 

  • Knoll J. Analysis of the pharmacologic effects of selective monoamine oxidase inhibitors. In Wolstenholme & Knight (Eds) Monoamine oxidase and its inhibition, pp. 135–161, Elsevier Press, Amsterdam, 1976

    Google Scholar 

  • Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. Journal of Clinical Psychiatry 51 (Suppl. 12B): 13–17, 1990

    PubMed  Google Scholar 

  • Koe BK, Koch SW, Lebel LA, Minor KW, Page MG. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of β-adrenoreceptor system of rat brain. European Journal of Pharmacology 141: 187–194, 1987

    Article  PubMed  CAS  Google Scholar 

  • Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-na-phthylamine, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacology and Experimental Therapeutics 226: 686–700, 1983

    PubMed  CAS  Google Scholar 

  • Kulig K. Management of poisoning associated with ‘newer’ antidepressant agents. Annals of Emergency Medicine 15: 1039–1045, 1986

    Article  PubMed  CAS  Google Scholar 

  • Lecrubier Y, Guelfi JD. Efficacy of reversible inhibition of monoamine oxidase-A in various forms of depression. Acta Psychiatrica Scandinavica 360 (Suppl.): 18–23, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics 43: 412–419, 1988

    Article  PubMed  CAS  Google Scholar 

  • Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 43 (Suppl. 2): 3–10, 1992

    Article  PubMed  CAS  Google Scholar 

  • Manji HK, Rudorfer MV, Potter WZ. The new-generation antidepressants, Part I. The First Wave. Drug Therapy 15: 683–700, 1990

    Google Scholar 

  • Masand MD, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. New England Journal of Medicine 324: 420, 1991

    PubMed  CAS  Google Scholar 

  • McGrath PJ, Quitkin FM, Harrison W, Stewart JW. Treatment of melancholia with tranylcypromine. American Journal of Psychiatry 141: 288–289, 1984

    PubMed  CAS  Google Scholar 

  • Mei-Tal V, Myers BS. Major psychiatric illness in the elderly: empirical study on an inpatient psychogeriatric unit. Part I; diagnostic complexities. International Journal of Psychiatric Medicine 15: 91–109, 1985

    Article  Google Scholar 

  • Mendelwicz J, Youdim MBH. L-deprenil, a selective monoamine oxidase type B inhibitor in the treatment of depression: a double-blind evaluation. British Journal of Psychiatry 142: 509–511, 1983

    Google Scholar 

  • Mindham RH, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychological Medicine 3: 5–17, 1973

    Article  PubMed  CAS  Google Scholar 

  • Murphy DL, Sunderland T, Cohen RM. Monoamine oxidase inhibiting antidepressants: a clinical update. The Psychiatric Clinics of North America 7: 549–562, 1984

    PubMed  CAS  Google Scholar 

  • Murphy DL, Lipper S, Campbell IC, et al. Comparative studies of MAO-B inhibitors. In Singer et al. (Eds) Man in monoamine oxidase structure, function and altered functions, pp. 457–475, Academic Press, New York, 1979

    Google Scholar 

  • Nierenberg AA, Cole JO. Antidepressant adverse drug reactions. Journal of Clinical Psychiatry 52 (Suppl. 6): 40–47, 1991

    PubMed  Google Scholar 

  • Nies A, et al. Changes in monoamine oxidase with aging. In Eisdorfer & Fann (Eds) Psychopharmacology and aging, pp. 41–54, Plenum Publishing Corp., New York, 1972

    Google Scholar 

  • Nies A, Robinson DS, Friedman MJ, Green R, Cooper T, et al. Relationship between age and tricyclic antidepressant plasma levels. American Journal of Psychiatry 134: 790–793, 1977

    PubMed  CAS  Google Scholar 

  • Ouslander JG. Drug therapy in the elderly. Annals of Internal Medicine 95: 711–722, 1981

    PubMed  CAS  Google Scholar 

  • Overall JE, Hollister LE, Shelton J. Tranylcypromine compared with dextroamphetamine in hospitalized depressed patients. Diseases of the Nervous System 27: 653–658, 1966

    PubMed  CAS  Google Scholar 

  • Pare CMB. The present status of monoamine oxidase inhibitors. British Journal of Psychiatry 146: 567–584, 1985

    Article  Google Scholar 

  • Pentel PR, Keyler DE, Haddad LM. Tricyclic and newer antidepressants. In Haddard & Winchester (Eds) Clinical management of poisoning and drug overdose, 2nd ed., pp. 636–655, W.B. Saunders, Philadelphia, 1990

    Google Scholar 

  • Perez-Stable EJ, Miranda J, Munoz RF, Ying YW. Depression in medical outpatients. Underrecognition and misdiagnosis. Archives of Internal Medicine 150: 1083–1088, 1990

    Article  PubMed  CAS  Google Scholar 

  • Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210: 88–90, 1980

    Article  PubMed  CAS  Google Scholar 

  • Plotkin DA, Gerson SC, Jarvik LF. Antidepressant drug treatment in the elderly. In Meltzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1149–1159, Raven Press, New York, 1987

    Google Scholar 

  • Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. New England Journal of Medicine 325: 633–642, 1991

    Article  PubMed  CAS  Google Scholar 

  • Prien RF. Long-term maintenance therapy in affective disorders. In Rifkin (Ed.) Schizophrenia and affective disorders, Biology and Drug Treatment, pp. 95–115, John Wright-PSG Inc., Boston, 1983

    Google Scholar 

  • Prien RF, Klett CJ, Caffay Jr EM. Lithium carbonate and imipramine in prevention of affective episodes. Archives of General Psychiatry 29: 420–425, 1973

    Article  PubMed  CAS  Google Scholar 

  • Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? American Journal of Psychiatry 143: 18–23, 1986

    PubMed  CAS  Google Scholar 

  • Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH collaborative study group comparing lithium carbonate, imipramine and a lithium carbonate-impramine combination. Archives of General Psychiatry 41: 1096–1104, 1984

    Article  PubMed  CAS  Google Scholar 

  • Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Archives of General Psychiatry 36: 749–760, 1979

    Article  PubMed  CAS  Google Scholar 

  • Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Archives of Internal Medicine 151: 754–756, 1991

    Article  PubMed  CAS  Google Scholar 

  • Reimherr FW, Chovinard G, Cohn CK, Cole JO, Itil TM, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multi-center comparison study in outpatients with major depression. Journal of Clinical Psychiatry 51 (Suppl. 12B): 18–27, 1990

    PubMed  Google Scholar 

  • Richelson E. Antidepressants: pharmacology and clinical use. In Karasu (Ed.) Treatment of psychiatric disorders, Vol. 3, pp. 1773–1787, American Psychiatric Association, Washington, DC, 1989

    Google Scholar 

  • Richelson E. Biological basis of depression and therapeutic relevance. Journal of Clinical Psychiatry 52 (Suppl. 6): 4–10, 1991

    PubMed  Google Scholar 

  • Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and Experimental Therapeutics 230: 94–100, 1984

    PubMed  CAS  Google Scholar 

  • Richie JL. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. New England Journal of Medicine 306: 954–959, 1982

    Article  Google Scholar 

  • Rickeis K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. Journal of Clinical Psychiatry 51 (Suppl. 12B): 9–12, 1990

    Google Scholar 

  • Risch SC, Janowsky DS, Huey LY. Plasma levels of tricyclic antidepressants and clinical efficacy. In Enna et al. (Eds) Antidepressants: neurochemical, behavioral and clinical perspectives, pp. 183–217, Raven Press, New York, 1981

    Google Scholar 

  • Robinson DS. Monoamine oxidase inhibitors and the elderly. In Raskin et al. (Eds) Age and the pharmacology of psychoactive drugs, pp. 151–162, Elsevier, New York, 1981

    Google Scholar 

  • Robinson DS, Cooper TB, Jindal SR, Corcella J, Lutz T. Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. Journal of Clinical Psychopharmacology 5: 333–337, 1985

    PubMed  CAS  Google Scholar 

  • Robinson DS, Davis JM, Nies A, Ravaris CL, Sylwester D. Relation of sex and aging to monoamine oxidase activity of human brain, plasma and platelets. Archives of General Psychiatry 24: 536–539, 1971

    Article  PubMed  CAS  Google Scholar 

  • Robinson DS, Kurtz NM. Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In Meltzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1297–1304, Raven Press, New York, 1987

    Google Scholar 

  • Roy A, DeJong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-year follow-up study. Archives of General Psychiatry 46: 609–612, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rudorfer MV, Manji HK, Potter WZ. The new-generation antidepressants, Part II. Fluoxetine and other selective reuptake inhibitors. Drug Therapy 15: 767–790, 1990a

    Google Scholar 

  • Rudorfer MV, Manji HK, Potter WZ. The new generation antidepressants, Part III. Bupropion and medications under development. Drug Therapy 15: 911–929, 1990b

    Google Scholar 

  • Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In Meltzer (Ed.) Psychopharmacology: third generation of progress, pp. 1353–1363, Raven Press, New York, 1987

    Google Scholar 

  • Rudorfer MV, Potter WZ. Antidepressants — a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 37: 713–738, 1989

    Article  PubMed  CAS  Google Scholar 

  • Ruegg RG, Ziscook S, Swerlow NR. Depression in the aged: an overview. Psychiatric Clinics of North America 11: 83–108, 1988

    PubMed  CAS  Google Scholar 

  • Salzman C, van der Kolk B. Treatment of depression. In Salzman (Ed.) Clinical geriatric psychopharmacology, pp. 77–115, McGraw-Hill, New York, 1984

    Google Scholar 

  • Schatzberg A, Dessian E, O’Neil P, Katz D, Cole J. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. Journal of Clinical Psychopharmacology 7: 44S–49S, 1987

    Article  PubMed  CAS  Google Scholar 

  • Seager CP, Bird RC. Imipramine with electrical treatment in depression — a controlled trial. Journal of Mental Science 108: 704–707, 1962

    PubMed  CAS  Google Scholar 

  • Serafimovski N, Thorball N, Asmussen I, Lunding M. Tricyclic antidepressive poisoning with special reference to cardiac complications. Acta Anaesthesiologica Scandinavica 57: 55–63, 1975

    Article  PubMed  CAS  Google Scholar 

  • Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology 9: 397–402, 1989

    Article  PubMed  CAS  Google Scholar 

  • Siever LJ, Uhde TW, Potter WZ, Murphy DL. Norepinephrine in the affective disorders: receptor assessment strategies. In Lake & Ziegler (Eds) The catecholamines in psychiatric and neurologic disorders, pp. 235–268, Butterworth, Boston, 1985

    Google Scholar 

  • Simpson GM, Pi EH. Plasma drug levels and clinical response to antidepressants. Journal of Clinical Psychiatry 44 (Suppl.): 27–44, 1983

    PubMed  CAS  Google Scholar 

  • Stanley M, Stanley B. Postmortem evidence for serotonin’s role in suicide. Journal of Clinical Psychiatry 51 (Suppl. 14): 22–28, 1990

    PubMed  Google Scholar 

  • Stein MK, Rickeis K, Weiss C. Maintenance therapy with amitriptyline: a controlled trial. American Journal of Psychiatry 137: 370–371, 1980

    PubMed  CAS  Google Scholar 

  • Stoeckel K, Pfefen JP, Mayersohn M, Schoerlin MP, Andressen C, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or renal function. Acta Psychiatrica Scandinavica 360 (Suppl.): 94–97, 1990

    Article  PubMed  CAS  Google Scholar 

  • Task Force on the use of laboratory tests in psychiatry: tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. American Journal of Psychiatry 142: 155–162, 1985

    Google Scholar 

  • Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry 147: 207–210, 1990

    PubMed  CAS  Google Scholar 

  • Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8: 186–212, 1993

    Article  PubMed  CAS  Google Scholar 

  • Thase ME. Relapse and recurrence in unipolar major depression: short-term and long-term approaches. Journal of Clinical Psychiatry 51 (Suppl. 6): 51–57, 1990

    PubMed  Google Scholar 

  • Triggs EJ, Nation RL. Pharmacokinetics in the aged: a review. Journal of Pharmacokinetics and Biopharmaceutics 3: 387–418, 1975

    PubMed  CAS  Google Scholar 

  • Versiani M, Nardi AE, Figueira IW, Stahl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A compared to other antidepressants and placebo. Acta Psychiatrica Scandinavica 360 (Suppl.): 24–28, 1990

    Article  PubMed  CAS  Google Scholar 

  • Waalinder J, Feighner JP. Novel selective serotonin reuptake inhibitors, Part I. Journal of Clinical Psychiatry 53: 107–112, 1992

    Google Scholar 

  • Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H. Review of fluvoxamine safety database. Drugs 43 (Suppl. 2): 48–54, 1992

    Article  PubMed  Google Scholar 

  • Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. Journal of Clinical Psychiatry 48: 244–245, 1987

    PubMed  CAS  Google Scholar 

  • Wells BG, Gelenberg AJ. Chemistry, pharmacology, pharmacokinetics, adverse effects and efficacy of the antidepressant maprotiline hydrochloride. Pharmacotherapy 1: 121–139, 1981

    PubMed  CAS  Google Scholar 

  • Zetin M, Aden G, Moldawsky R. Tolerance to amoxapine antidepressant effects. Clinical Therapeutics 5: 638–643, 1983

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Clinical Research Unit, University of Arizona Health Sciences Center, Tucson, Arizona, 85724, USA

    Rubin Bressler

  2. Department of Pharmacy Practice, College of Pharmacy, University of Arizona, Tucson, Arizona, USA

    Michael D. Katz

Authors
  1. Rubin Bressler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael D. Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bressler, R., Katz, M.D. Drug Therapy for Geriatric Depression. Drugs & Aging 3, 195–219 (1993). https://doi.org/10.2165/00002512-199303030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199303030-00002

Keywords

Search

Navigation